The financing (around €19m) shall fully fund the commencement of a potentially pivotal/registrational Phase 2/3 study for KL1333 and its progression to the outcome of a key interim analysis.
https://european-biotechnology.com/wp-content/uploads/2024/04/columbia_mito-1500x632-2.jpg540960Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2022-06-02 15:54:002024-04-04 16:46:43Abliva decides on a SEK200m financing to fund Phase 2/3 study